Sign Out
Fondaparinux does not markedly inhibit CYP450s (CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 or CYP3A4) in vitro. Thus, ARIXTRA is not expected to interact with other medicinal products in vivo by inhibition of CYP-mediated metabolism.
Since fondaparinux does not bind significantly to plasma proteins other than ATIII, no interaction with other medicinal products by protein binding displacement are expected.
In clinical studies performed with fondaparinux, the concomitant use of warfarin (oral anticoagulant), acetylsalicylic acid (platelet inhibitor), piroxicam (non-steroidal anti-inflammatory), and digoxin (cardiac glycoside) did not significantly affect the pharmacokinetics or pharmacodynamics of fondaparinux. In addition fondaparinux neither influenced the INR activity of warfarin, nor the bleeding time under acetylsalicylic acid or piroxicam treatment, nor the pharmacokinetics or pharmacodynamics of digoxin at steady state.
